FI945592A - Fosfonosulfonaattiyhdisteitä epänormaalin kalsium- ja fosfaattiaineenvaihdunnan hoitamiseksi - Google Patents
Fosfonosulfonaattiyhdisteitä epänormaalin kalsium- ja fosfaattiaineenvaihdunnan hoitamiseksi Download PDFInfo
- Publication number
- FI945592A FI945592A FI945592A FI945592A FI945592A FI 945592 A FI945592 A FI 945592A FI 945592 A FI945592 A FI 945592A FI 945592 A FI945592 A FI 945592A FI 945592 A FI945592 A FI 945592A
- Authority
- FI
- Finland
- Prior art keywords
- present
- treatment
- phosphate metabolism
- abnormal calcium
- relates
- Prior art date
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title abstract 2
- LQHYUUBBIJGBNR-UHFFFAOYSA-N OP(O)(=O)S(O)(=O)=O Chemical class OP(O)(=O)S(O)(=O)=O LQHYUUBBIJGBNR-UHFFFAOYSA-N 0.000 title abstract 2
- 229910019142 PO4 Inorganic materials 0.000 title abstract 2
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- 229910052791 calcium Inorganic materials 0.000 title abstract 2
- 239000011575 calcium Substances 0.000 title abstract 2
- 230000004060 metabolic process Effects 0.000 title abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title abstract 2
- 239000010452 phosphate Substances 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5532—Seven-(or more) membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/5765—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Removal Of Specific Substances (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89149092A | 1992-05-29 | 1992-05-29 | |
| US89130992A | 1992-05-29 | 1992-05-29 | |
| US89088692A | 1992-05-29 | 1992-05-29 | |
| US89135592A | 1992-05-29 | 1992-05-29 | |
| US89088592A | 1992-05-29 | 1992-05-29 | |
| US89148792A | 1992-05-29 | 1992-05-29 | |
| US08/055,809 US5731299A (en) | 1992-05-29 | 1993-05-07 | Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| PCT/US1993/004976 WO1993024495A1 (en) | 1992-05-29 | 1993-05-26 | Phosphonosulfonate compounds for treating abnormal calcium and phosphate metabolism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI945592A0 FI945592A0 (fi) | 1994-11-28 |
| FI945592A true FI945592A (fi) | 1994-11-28 |
Family
ID=27568101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI945592A FI945592A (fi) | 1992-05-29 | 1994-11-28 | Fosfonosulfonaattiyhdisteitä epänormaalin kalsium- ja fosfaattiaineenvaihdunnan hoitamiseksi |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0642518B1 (fi) |
| JP (1) | JP3781769B2 (fi) |
| CN (3) | CN1087640A (fi) |
| AT (1) | ATE169302T1 (fi) |
| AU (1) | AU659565B2 (fi) |
| CA (1) | CA2136823C (fi) |
| CZ (1) | CZ295894A3 (fi) |
| DE (1) | DE69320187T2 (fi) |
| DK (1) | DK0642518T3 (fi) |
| ES (1) | ES2123057T3 (fi) |
| FI (1) | FI945592A (fi) |
| HU (1) | HUT71907A (fi) |
| IL (1) | IL105839A (fi) |
| MX (1) | MX9303242A (fi) |
| NO (1) | NO305958B1 (fi) |
| NZ (1) | NZ253523A (fi) |
| SG (1) | SG90009A1 (fi) |
| SK (1) | SK145594A3 (fi) |
| WO (1) | WO1993024495A1 (fi) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731299A (en) * | 1992-05-29 | 1998-03-24 | The Procter & Gamble Company | Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| CA2107644A1 (en) * | 1992-10-28 | 1994-04-29 | David R. Magnin | .alpha.-phosphonosulfonae squalene synthetase inhibitors and methd |
| US5470845A (en) * | 1992-10-28 | 1995-11-28 | Bristol-Myers Squibb Company | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia |
| US5447922A (en) * | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
| US5618964A (en) * | 1995-06-07 | 1997-04-08 | Bristol-Myers Squibb Company | Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method |
| CN106883165B (zh) * | 2017-01-03 | 2019-03-26 | 中节能万润股份有限公司 | 一种模板剂中间体的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT352142B (de) * | 1977-03-29 | 1979-09-10 | Benckiser Knapsack Gmbh | Verfahren zur herstellung von neuen n- sulfoalkan-aminoalkanphosphonsaeuren und deren alkalisalzen |
| DE3434667A1 (de) * | 1984-09-21 | 1986-04-03 | Henkel KGaA, 4000 Düsseldorf | 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung |
| IL77243A (en) * | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
| IL86951A (en) * | 1987-07-06 | 1996-07-23 | Procter & Gamble Pharma | Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them |
| IL86095A0 (fi) * | 1987-09-30 | 1988-09-30 | Lilly Co Eli | |
| KR900011782A (ko) * | 1989-01-03 | 1990-08-02 | 추후보정 | 불화 포스포노술폰산 및 그의 유도체 |
| US5731299A (en) * | 1992-05-29 | 1998-03-24 | The Procter & Gamble Company | Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
-
1993
- 1993-05-26 CA CA002136823A patent/CA2136823C/en not_active Expired - Fee Related
- 1993-05-26 HU HU9403411A patent/HUT71907A/hu unknown
- 1993-05-26 WO PCT/US1993/004976 patent/WO1993024495A1/en not_active Application Discontinuation
- 1993-05-26 SG SG9607956A patent/SG90009A1/en unknown
- 1993-05-26 SK SK1455-94A patent/SK145594A3/sk unknown
- 1993-05-26 JP JP50072194A patent/JP3781769B2/ja not_active Expired - Fee Related
- 1993-05-26 AU AU43916/93A patent/AU659565B2/en not_active Ceased
- 1993-05-26 ES ES93914150T patent/ES2123057T3/es not_active Expired - Lifetime
- 1993-05-26 AT AT93914150T patent/ATE169302T1/de not_active IP Right Cessation
- 1993-05-26 DE DE69320187T patent/DE69320187T2/de not_active Expired - Fee Related
- 1993-05-26 DK DK93914150T patent/DK0642518T3/da active
- 1993-05-26 NZ NZ253523A patent/NZ253523A/en unknown
- 1993-05-26 CZ CZ942958A patent/CZ295894A3/cs unknown
- 1993-05-26 EP EP93914150A patent/EP0642518B1/en not_active Expired - Lifetime
- 1993-05-28 IL IL10583993A patent/IL105839A/xx not_active IP Right Cessation
- 1993-05-29 CN CN93108418A patent/CN1087640A/zh active Pending
- 1993-05-31 MX MX9303242A patent/MX9303242A/es not_active IP Right Cessation
-
1994
- 1994-11-24 NO NO944498A patent/NO305958B1/no not_active IP Right Cessation
- 1994-11-28 FI FI945592A patent/FI945592A/fi unknown
-
1999
- 1999-01-20 CN CN99101270A patent/CN1229083A/zh active Pending
- 1999-09-06 CN CN99118825A patent/CN1255501A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX9303242A (es) | 1994-05-31 |
| CN1255501A (zh) | 2000-06-07 |
| CA2136823C (en) | 1998-05-26 |
| ATE169302T1 (de) | 1998-08-15 |
| AU4391693A (en) | 1993-12-30 |
| NZ253523A (en) | 1997-01-29 |
| ES2123057T3 (es) | 1999-01-01 |
| JP3781769B2 (ja) | 2006-05-31 |
| DK0642518T3 (da) | 1998-12-14 |
| FI945592A0 (fi) | 1994-11-28 |
| SK145594A3 (en) | 1995-07-11 |
| SG90009A1 (en) | 2002-07-23 |
| DE69320187D1 (de) | 1998-09-10 |
| CN1229083A (zh) | 1999-09-22 |
| DE69320187T2 (de) | 1999-02-11 |
| JPH07507314A (ja) | 1995-08-10 |
| NO944498L (no) | 1995-01-26 |
| WO1993024495A1 (en) | 1993-12-09 |
| HUT71907A (en) | 1996-02-28 |
| HU9403411D0 (en) | 1995-02-28 |
| EP0642518A1 (en) | 1995-03-15 |
| NO305958B1 (no) | 1999-08-23 |
| EP0642518B1 (en) | 1998-08-05 |
| CZ295894A3 (en) | 1995-10-18 |
| NO944498D0 (no) | 1994-11-24 |
| IL105839A (en) | 2001-08-26 |
| CN1087640A (zh) | 1994-06-08 |
| CA2136823A1 (en) | 1993-12-09 |
| IL105839A0 (en) | 1993-09-22 |
| AU659565B2 (en) | 1995-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO944515D0 (no) | Fosfonkarboksylatforbindelser for behandling av abnormal kalsium- og fosfatmetabolisme | |
| RU94046137A (ru) | Фосфонсульфонатные соединения для лечения аномального кальциевого и фосфатного обмена, фармацевтическая композиция | |
| RU94046146A (ru) | Тиозамещенные азотсодержащие гетероциклические фосфонатные соединения, фармкомпозиция и способ лечения | |
| CA2188066A1 (en) | Thio-Substituted Phosphonate Compounds | |
| FI945592A (fi) | Fosfonosulfonaattiyhdisteitä epänormaalin kalsium- ja fosfaattiaineenvaihdunnan hoitamiseksi | |
| FI945597A (fi) | Kvartäärisiä typpipitoisia fosfonaattiyhdisteitä epänormaalin kalsium- ja fosfaattiaineenvaihdunnan hoitamiseksi | |
| CA2136822A1 (en) | Thio-Substituted Cyclic Phosphonate Compounds for Treating Abnormal Calcium and Phosphate Metabolism | |
| RU94046139A (ru) | Содержащие четвертичный азот фосфанатные соединения для лечения аномального кальциевого и фосфатного метаболизма, фармацевтическая композиция | |
| RU94046138A (ru) | Тиозамещенные циклические фосфонатные соединения для лечения аномального кальциевого и фосфатного метаболизма, фармацевтическая композиция, способ лечения |